Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma.

Storandt, Michael H; Gile, Jennifer J; Palmer, Mathias E; Zemla, Tyler J; Ahn, Daniel H; Bekaii-Saab, Tanios S; Jin, Zhaohui; Tran, Nguyen H; Mahipal, Amit

Storandt, Michael H; Gile, Jennifer J; Palmer, Mathias E; Zemla, Tyler J; Ahn, Daniel H; Bekaii-Saab, Tanios S; Jin, Zhaohui; Tran, Nguyen H; Mahipal, Amit.

Afiliação

Storandt MH; Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Gile JJ; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Palmer ME; Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Zemla TJ; Department of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
Ahn DH; Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.
Bekaii-Saab TS; Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.
Jin Z; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Tran NH; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Mahipal A; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.

Cancers (Basel) ; 14(21)2022 Oct 22.

Article em En | MEDLINE | ID: mdl-36358592

Palavras-chave

cabozantinib; hepatocellular cancer; immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google